Alexander J Muller

Summary

Affiliation: Lankenau Institute for Medical Research
Country: USA

Publications

  1. ncbi request reprint Indoleamine 2,3-dioxygenase in immune suppression and cancer
    Alexander J Muller
    Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
    Curr Cancer Drug Targets 7:31-40. 2007
  2. ncbi request reprint Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors
    Alexander J Muller
    Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
    Expert Opin Ther Targets 9:831-49. 2005
  3. ncbi request reprint Marrying immunotherapy with chemotherapy: why say IDO?
    Alexander J Muller
    Lankenau Institute for Medical Research, Wynnewood, Pennsylvania 19096, USA
    Cancer Res 65:8065-8. 2005
  4. ncbi request reprint Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
    Alexander J Muller
    Lankenau Institute for Medical Research, Wynnewood, Pennsylvania 19096, USA
    Nat Rev Cancer 6:613-25. 2006
  5. pmc Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion
    Alexander J Muller
    Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
    Cancer Immunol Immunother 59:1655-63. 2010
  6. ncbi request reprint Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy
    Alexander J Muller
    Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood, Pennsylvania 19096, USA
    Nat Med 11:312-9. 2005
  7. ncbi request reprint Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer
    Mee Young Chang
    Lankenau Institute for Medical Research, Lankenau Hospital, Wynnewood, Pennsylvania 19096, USA
    Cancer Res 67:7605-12. 2007
  8. pmc IDO is a nodal pathogenic driver of lung cancer and metastasis development
    Courtney Smith
    Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA
    Cancer Discov 2:722-35. 2012
  9. pmc Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase
    Mee Young Chang
    Lankenau Institute for Medical Research, Wynnewood, PA USA
    Cancer Biol Ther 12:1050-8. 2011
  10. ncbi request reprint Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression
    Mee Young Chang
    Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood, PA 19096, USA
    Cancer Res 67:100-7. 2007

Collaborators

  • George C Prendergast
  • Laura Mandik-Nayak
  • Lisa D Laury-Kleintop
  • Wei Du
  • Yan Wang
  • Suzanne Ostrand-Rosenberg
  • Courtney Smith
  • David H Munn
  • ANDREW LEE MELLOR
  • Mee Young Chang
  • James B DuHadaway
  • Janette Boulden
  • Sanjeev Kumar
  • Alejandro Peralta Soler
  • Jessica B Katz
  • Richard Metz
  • Alejandro P Soler
  • Grant N Scott
  • Daniel Jaller
  • Arivudainambi Ramalingam
  • Judith M LaLonde
  • William P Malachowski
  • James DuHadaway
  • Erika Sutanto-Ward
  • De Yan Hou
  • James M Mullin
  • M Carmen Valenzano
  • Jennifer R Pyle
  • Elizabeth Pigott
  • Natalie Ridge
  • Bhumika Patel
  • Preston S Donover
  • Patrick J Carroll
  • Joseph Dinchuk
  • Melinda K Duncan
  • Minzhou Huang
  • Lois M McNally
  • Madhav D Sharma
  • Liwei Wang
  • Tinku Banerjee
  • Uma Kamasani
  • Maribeth Johnson
  • Thomas J Meyer
  • Diane M Sharp
  • Scott Donover
  • Ai xue Liu
  • Judith Baker

Detail Information

Publications25

  1. ncbi request reprint Indoleamine 2,3-dioxygenase in immune suppression and cancer
    Alexander J Muller
    Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
    Curr Cancer Drug Targets 7:31-40. 2007
    ..This essay summarizes key findings that implicate IDO as an important mediator of peripheral tolerance and discusses the development of anti-cancer modalities that incorporate the use of IDO inhibitors...
  2. ncbi request reprint Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors
    Alexander J Muller
    Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
    Expert Opin Ther Targets 9:831-49. 2005
    ..The second part focuses on the current state of development of IDO inhibitory compounds as potential pharmaceutical agents...
  3. ncbi request reprint Marrying immunotherapy with chemotherapy: why say IDO?
    Alexander J Muller
    Lankenau Institute for Medical Research, Wynnewood, Pennsylvania 19096, USA
    Cancer Res 65:8065-8. 2005
    ..By promoting antitumor immune responses in combination with cytotoxic chemotherapy, IDO inhibitors may offer a drug-based strategy to more effectively attack systemic cancer...
  4. ncbi request reprint Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
    Alexander J Muller
    Lankenau Institute for Medical Research, Wynnewood, Pennsylvania 19096, USA
    Nat Rev Cancer 6:613-25. 2006
    ..Within the context of the pathophysiology of cancer-associated immune tolerance, this Review delineates potential molecular targets for therapeutic intervention and the progress that has been made in developing small-molecule inhibitors...
  5. pmc Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion
    Alexander J Muller
    Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
    Cancer Immunol Immunother 59:1655-63. 2010
    ..More generally, they promote the concept that mediators of immune escape and cancer-associated inflammation may be genetically synonymous...
  6. ncbi request reprint Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy
    Alexander J Muller
    Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood, Pennsylvania 19096, USA
    Nat Med 11:312-9. 2005
    ..Our findings suggest that Bin1 loss promotes immune escape in cancer by deregulating IDO and that IDO inhibitors may improve responses to cancer chemotherapy...
  7. ncbi request reprint Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer
    Mee Young Chang
    Lankenau Institute for Medical Research, Lankenau Hospital, Wynnewood, Pennsylvania 19096, USA
    Cancer Res 67:7605-12. 2007
    ..Taken together, our findings highlight an important role for Bin1 as a negative modifier of inflammation and cancer susceptibility during aging...
  8. pmc IDO is a nodal pathogenic driver of lung cancer and metastasis development
    Courtney Smith
    Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA
    Cancer Discov 2:722-35. 2012
    ..Together, our findings define IDO as a prototypical integrative modifier that bridges inflammation, vascularization, and immune escape to license primary and metastatic tumor outgrowth...
  9. pmc Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase
    Mee Young Chang
    Lankenau Institute for Medical Research, Wynnewood, PA USA
    Cancer Biol Ther 12:1050-8. 2011
    ..Together, our findings suggest potential cardiac and gastrointestinal risks of IDO inhibitors that should be monitored in patients as this new class of drugs enter early clinical development...
  10. ncbi request reprint Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression
    Mee Young Chang
    Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood, PA 19096, USA
    Cancer Res 67:100-7. 2007
    ..These findings suggest that Bin1 loss cooperates with ras activation to drive progression, establishing a role for Bin1 as a negative modifier of oncogenicity and progression in breast cancer...
  11. doi request reprint Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape
    Jessica B Katz
    Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
    Immunol Rev 222:206-21. 2008
    ....
  12. pmc Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate
    Alexander J Muller
    Lankenau Institute for Medical Research, Wynnewood, Pennsylvania 19096, USA
    Cancer Res 70:1845-53. 2010
    ..Further, these findings rationalize oncologic applications for this agent by providing a compelling basis to reposition ethyl pyruvate as a low-cost immunochemotherapy for clinical evaluation in cancer patients...
  13. ncbi request reprint Targeted deletion of the suppressor gene bin1/amphiphysin2 accentuates the neoplastic character of transformed mouse fibroblasts
    Alexander J Muller
    Lankenau Institute for Medical Research, Wynnewood, Pennsylvania 19096, USA
    Cancer Biol Ther 3:1236-42. 2004
    ..These findings offer a novel line of support for the hypothesized role of Bin1 in limiting malignant growth, possibly as a negative modifier or anti-progression gene...
  14. pmc BAR the door: cancer suppression by amphiphysin-like genes
    George C Prendergast
    Lankenau Institute for Medical Research, Wynnewood PA, USA
    Biochim Biophys Acta 1795:25-36. 2009
    ....
  15. pmc Bin1 attenuation suppresses experimental colitis by enforcing intestinal barrier function
    Mee Young Chang
    Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
    Dig Dis Sci 57:1813-21. 2012
    ..Thus, identifying genes that could be targeted to enforce tight junctions and improve barrier function may lead to new treatment strategies for IBD...
  16. doi request reprint Bin3 deletion causes cataracts and increased susceptibility to lymphoma during aging
    Arivudainambi Ramalingam
    Lankenau Institute for Medical Research, Wynnewood, Pennsylvania 19096, USA
    Cancer Res 68:1683-90. 2008
    ..Our findings establish functions for Bin3 in lens development and cancer suppression during aging. Further, they define Bin3 as a candidate for an unidentified tumor suppressor that exists at the human chromosome 8p21.3 locus...
  17. pmc The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity
    Grant N Scott
    The Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
    J Immunol 182:7509-17. 2009
    ..We suggest that IDO is not simply immunosuppressive, but rather plays a more complex role in modulating inflammatory responses, in particular those that are driven by autoreactive B cells...
  18. ncbi request reprint Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan
    Richard Metz
    Lankenau Institute for Medical Research, Wynnewood, Pennsylvania 19096, USA
    Cancer Res 67:7082-7. 2007
    ....
  19. ncbi request reprint Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
    George C Prendergast
    Lankenau Institute for Medical Research LIMR, 100 Lancaster Avenue, Wynnewood, PA, 19096, USA
    Cancer Immunol Immunother 63:721-35. 2014
    ....
  20. pmc Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway
    George C Prendergast
    Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
    Am J Pathol 176:2082-7. 2010
    ....
  21. ncbi request reprint Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1
    James B DuHadaway
    Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
    Oncogene 22:3578-88. 2003
    ....
  22. ncbi request reprint Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses
    De Yan Hou
    Immunotherapy Center and Departments of Pediatrics, Medicine, and Biostatistics, Medical College of Georgia, Augusta, Georgia
    Cancer Res 67:792-801. 2007
    ....
  23. pmc Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase
    Sanjeev Kumar
    Department of Chemistry, Bryn Mawr College, Bryn Mawr, Pennsylvania 19010, USA
    J Med Chem 51:4968-77. 2008
    ..The study represents the first example of enzyme inhibitor development with the recently reported crystal structure of IDO and offers important lessons in the search for more potent inhibitors...
  24. doi request reprint Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors
    Sanjeev Kumar
    Department of Chemistry, Bryn Mawr College, Bryn Mawr, PA 19010, USA
    J Med Chem 51:1706-18. 2008
    ..Synthetic accessibility of this class will facilitate preclinical chemical-genetic studies as well as further optimization of pharmacological parameters for clinical translation...